Clearside Biomedical to Report Second Quarter 2024 Financial Results on Monday, August 12, 2024

8/1/24 7:05:00 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $CLSD alert in real time by email

ALPHARETTA, Ga., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS^®), announced today that its second quarter 2024 financial results will be reported on Monday, August 12, 2024, after the close of the financial markets.

In lieu of a second quarter 2024 conference call, the Company hosted a Suprachoroidal Delivery Key Opinion Leader Webinar on Wednesday, July 24, 2024. The replay of this event is available on the Clearside website under the Investors section: Events and Presentations. Quarterly earnings conference calls are expected to resume with the third quarter 2024 financial results.

About Clearside Biomedical, Inc.

Clearside Biomedical, Inc. is a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS^®). Clearside's SCS injection platform, utilizing the Company's patented SCS Microinjector^®, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases. Clearside is developing its own pipeline of small molecule product candidates for administration via its SCS Microinjector. The Company's lead program, CLS-AX (axitinib injectable suspension), for the treatment of neovascular age-related macular degeneration (wet AMD), is in Phase 2b clinical testing. Clearside developed and gained approval for its first product, XIPERE ^® (triamcinolone acetonide injectable suspension) for suprachoroidal use, which is available in the U.S. through a commercial partner. Clearside also strategically partners its SCS injection platform with companies utilizing other ophthalmic therapeutic innovations. For more information, please visit clearsidebio.com and follow us on LinkedIn and X.

Investor and Media Contacts:

Jenny Kobin

Remy Bernarda

[email protected]

(678) 430-8206

Source: Clearside Biomedical, Inc.

Get the next $CLSD alert in real time by email

Date

Price Target

Rating

Analyst

8/21/2024

$6.00

Buy

Chardan Capital Markets

6/25/2024

$5.00

Outperform

Oppenheimer

3/11/2022

$11.00 → $10.00

Market Outperform

JMP Securities

12/15/2021

$19.00 → $9.00

Outperform

Wedbush

7/29/2021

$10.00

Buy

HC Wainwright & Co.

Clearside Biomedical to Report Second Quarter 2024 Financial Results on Monday, August 12, 2024

Chat with this insight

Recent Analyst Ratings for $CLSD

$CLSD Press Releases

Fastest customizable press release news feed in the world

Clearside Biomedical Announces Third Quarter 2024 Financial Results and Provides Corporate Update

Clearside Biomedical Partner Arctic Vision Executes Commercial Collaboration Agreement with Santen Pharmaceutical Co., Ltd for ARVN001 Suprachoroidal Space Injection Therapy for the Treatment of Uveitic Macular Edema

Clearside Biomedical to Participate in Fireside Chat at the Stifel 2024 Healthcare Conference

$CLSD Market Insights

Live Market Insights

Needham Reiterates Buy on Clearside Biomedical, Maintains $4 Price Target

Why Is Clearside Biomedical Stock Gaining Today?

Clearside Biomedical shares are trading higher after Oppenheimer initiated coverage with an Outperform rating and a price target of $5.

$CLSD Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Chardan Capital Markets initiated coverage on Clearside Biomedical with a new price target

Oppenheimer initiated coverage on Clearside Biomedical with a new price target

JMP Securities reiterated coverage on Clearside Biomedical with a new price target

$CLSD Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Chief Medical Officer Chong Ngai Hang Victor bought $36,500 worth of shares (36,500 units at $1.00), increasing direct ownership by 57% to 100,000 units (SEC Form 4)

Chief Medical Officer Chong Ngai Hang Victor bought $24,910 worth of shares (23,500 units at $1.06), increasing direct ownership by 59% to 63,500 units (SEC Form 4)

Amendment: New insider Chong Ngai Hang Victor claimed ownership of 10,000 shares (SEC Form 3)

$CLSD Financials

Live finance-specific insights

Clearside Biomedical Announces Third Quarter 2024 Financial Results and Provides Corporate Update

Clearside Biomedical to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Tuesday, November 12, 2024

Clearside Biomedical Announces Positive Topline Results from ODYSSEY Phase 2b Trial of Suprachoroidal CLS-AX in Wet AMD Achieving All Primary and Secondary Outcomes

$CLSD Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G/A filed by Clearside Biomedical Inc. (Amendment)

SEC Form SC 13G/A filed by Clearside Biomedical Inc. (Amendment)

SEC Form SC 13G/A filed by Clearside Biomedical Inc. (Amendment)

$CLSD FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

FDA Approval for XIPERE issued to CLEARSIDE BIOMEDICAL, INC

FDA Approval for SUSVIMO issued to CLEARSIDE BIOMEDICAL, INC

$CLSD Leadership Updates

Live Leadership Updates

Clearside Biomedical Appoints Tony Gibney as New Chair of the Board of Directors

Clearside Biomedical Appoints Dr. Glenn Yiu to its Scientific Advisory Board

Clearside Biomedical Appoints Seasoned Biotechnology Executive Anthony S. Gibney to its Board of Directors

$CLSD Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Chief Medical Officer Chong Ngai Hang Victor bought $36,500 worth of shares (36,500 units at $1.00), increasing direct ownership by 57% to 100,000 units (SEC Form 4)

Chief Medical Officer Chong Ngai Hang Victor bought $24,910 worth of shares (23,500 units at $1.06), increasing direct ownership by 59% to 63,500 units (SEC Form 4)

Yerxa Benjamin R bought $10,235 worth of shares (7,813 units at $1.31), increasing direct ownership by 77% to 17,957 units (SEC Form 4)

$CLSD SEC Filings

SEC Form 10-Q filed by Clearside Biomedical Inc.

Clearside Biomedical Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

Clearside Biomedical Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

Recent Analyst Ratings for
$CLSD

$CLSD
Press Releases

$CLSD
Market Insights

$CLSD
Analyst Ratings

$CLSD
Insider Trading

$CLSD
Financials

$CLSD
Large Ownership Changes

$CLSD
FDA approvals

$CLSD
Leadership Updates

$CLSD
Insider Purchases

$CLSD
SEC Filings